TP53 and central nervous system cancer: Using gene editing protocol based on CRISPR-Cas 9 with cytidine deaminase, we established genetically modified U87MG glioblastoma cell lines with the heterozygous IDH1 R132H genotype (IDH1het), homozygous TP53 R248Q genotype (TP53homo) and combined heterozygous IDH1 R132H, homozygous TP53 R248Q genotype (IDH1het-TP53homo) to promote a comprehensive analysis of cell migration and adhesion on major ECM components, aiming to elucidate IDH1 R132H and TP53 R248Q’s impact on glioma cell migration.